Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Mid-Term Functionality and Survival of 116 HemiCAP® Implants for Hallux Rigidus

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Overnight Admission After Total Ankle Replacement - Is It Safe?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The Effect of a Single Hyaluronic Acid Injection in Ankle Arthritis - A Prospective Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Surgical Repair of Complete Plantar Fascia Ruptures in High-Demand Power Athletes: An Alternative Treatment Option

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Severe Functional Debilitations After Complications Associated With Acute Achilles Tendon Rupture With 9 Years of Follow-Up

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Social Distancing Policies in the Coronavirus Battle: A Comparison of Denmark and Sweden

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Using MR elastography to assess portal hypertension and response to beta-blockers in patients with cirrhosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. suPAR Cut-Offs for Risk Stratification in Patients With Symptoms of COVID-19

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Hallux rigidus can be treated with a proximal hemiarthroplasty (HemiCAP®) to preserve the motion in the first metatarsophalangeal joint and reduce pain. This study examines the functionality, and survival rates of HemiCAP® implants, with or without a dorsal flange. One hundred and five patients were treated with a HemiCAP® (N = 116 HemiCAPs®) between 2006 and 2014. Revision rates, arthrosis score, hallux valgus (HV), intermetatarsal (IM), distal metaphyseal articular angle (DMAA), visual analog scale (VAS) (1-10 points), American Orthopaedic Foot and Ankle Score (AOFAS) MTP-IP (AOFAS 0-100 points), SF-12, range of motion (ROM), and radiographs were analyzed pre- and postoperatively. Statistics: Kaplan-Meier survival analysis, Cox-regression, and paired t tests. At 2, 4, and 6 years, the implant survival was 87%, 83%, and 81%, respectively. All revised due to pain. Dorsal flange, gender, arthrosis, HV, IM, and DMAA did not influence the results. At the mean 5-year follow-up (n = 47) median (range) dorsal ROM was 45° (10°-75°), AOFAS was mean 87.2 ± 10.8, VAS was 2 ± 1.6, and SEFAS was 42 ± 6 points. The dorsal flange made no significant difference for ROM or patient-reported outcome measures compared to the HemiCAP® with no dorsal flange. Twenty-three patients with preoperative data were re-examined, and preoperative dorsal ROM mean difference (confidence interval [CI]) increased 20.7° (13.9°-27.4°), VAS decreased with a mean difference (CI) of -4.7 (-5.8 to 3.5), and AOFAS increased with a mean difference (CI) 26.2 (20.2-32.2) (for all p < .001). The 6-year survival rate of the HemiCAP® implant was 81%. The design change to dorsal flange was not evident clinically. Unrevised patients had significantly less pain, greater ROM, and better foot and ankle function than preoperatively.

OriginalsprogEngelsk
Artikelnummer1053
TidsskriftThe Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons
Vol/bind60
Udgave nummer2
Sider (fra-til)322-327
Antal sider6
ISSN1067-2516
DOI
StatusUdgivet - 1 mar. 2021

ID: 61730760